The Cancer Research Foundation makes ad hoc grants to support ground-breaking research projects in science. ONe of our most recent programs is the Small Cell Lung Cancer Project, a team science initiative aimed at small cell lung cancer, a recalcitrant disease which shows promise as a proxy for other small cell and recalcitrant cancers.
The Small Cell Lung Cancer Program
Multiple Principle Investigators · University of Chicago
The Cancer Research Foundation is pleased to announce its latest team science grant assembling an all-star lineup of University of Chicago researchers and clinicians, focused on small cell lung cancer, a deadly and recalcitrant disease that shows promised as a proxy for many cancers that have been left behind in recent advances in cancer care and survival.
Tumor-intrinsic, germline and environmental correlates of the response to checkpoint immunotherapy in patients with advanced cancer
Jason Luke, MD, Paolo Ascierto, MD, HIroyoshi NIshikawa, MD, PhD ·
Immunotherapy for cancer has become an essential element of treatment for multiple cancer types. However, many cancer types show no effect at all. This study proposes to collect an array of samples from patients in very different geographic locations to study why treatment outcomes vary so much.
Identifying Germline Mutations In Young Patients with MDS
PRINCIPAL INVESTIGATORS: Lucy Godley, MD, PhD - University of Chicago · Carolyn Owen, MD - University of Calgary
This study will be the first to examine the frequency of germline mutations in MDS patients 40 years old or younger, generating data on new alleles that are likely to disrupt bone marrow function and normal blood cell development. This work will also define a group of patients in this cohort with no recognizable mutations by MarrowSeq screening, who will serve as subjects for future non-biased sequencing studies (examining the entire exome) to discover new genes implicated in familial hematopoietic malignancies. Other studies using the MarrowSeq panel are also possible, including examining patients with refractory idiopathic thrombocytopenic purpura, a fraction of whom is likely to also have a genetic basis for their disease.
The Interdiscipinary Leukemia Project
Multiple Principal Investigators · University of Chicago
A major new grant to support novel science in cancer research: The Interdisciplinary Leukemia Project, a six-part systems biology-based interdisciplinary attack on therapy-based Acute Myeloid Leukemia, a secondary cancer that strikes 8 to 10% of cancer survivors.
The Cancer Research Foundation Program in GI Cancer Prevention And Control
Principal Investigator: Nathan Ellis · University of Chicago
In 2005, the CRF made a $1.5 Million grant to the University of Chicago Cancer Research Center (UCCRC) to launch the Cancer Research Foundation Program in Gastrointestinal (GI) Cancer to aid in the building of a comprehensive cancer program, leading efforts in population-based research, genetic risk assessment, computational biology, cancer prevention, detection and treatment. This grant has helped build infrastructure for the GI Program; expand the GI Program model into other cancer areas; and obtain comprehensive status from the National Cancer Institute.
The Bernice Goldblatt Pediatric Pharmacogentics Program
Principal Investigators: Dr. Ramamoorthy Nagasubramanian, Dr. John Cunningham · University of Chicago
In 2004 the Cancer Research Foundation awarded $500,000 to establish a Pediatric Pharmacogenetics Program at the University of Chicago. The overall goal of this project is to discover molecular determinants that influence anticancer drug response and toxicity in patients with sarcoma.
"The most significant science is a process of exploration and is definitely not for the faint-hearted. You have a few clues and a hunch that 'there is something out there', but most of the time you are definitely 'flying by the seat of your pants'. After all, there are no familiar landmarks in truly unexplored territory. Who will finance such a risky business? Certainly not the government and other large organizations. Such groups support the development of new areas only after an initial discovery has made it obvious to everyone that there is something to be gained. In my experience, the Cancer Research Foundation had been one of the only groups that has been willing to bear the risk of the all-important fist step in a new project. Specifically, the CRF was instrumental in nurturing our early efforts to create multimodality 3D images of brain structure and function. These methods are now in use in many brain research laboratories around the world."
David N. Levin, M.D., Ph.D.
Professor, Department of Radiology Director, Maurice Goldblatt Magnetic Resonance Imaging Center The University of Chicago
April 30, 2010